Polyrizon Targets $3.15B Epilepsy Market with Preclinical Studies for Innovative Rescue Treatment
Polyrizon Ltd. (NASDAQ: PLRZ) has initiated preclinical studies for intranasal Benzodiazepines (BZDs) using its proprietary Trap and Target™ (T&T) platform to treat acute repetitive seizures (ARS) and status epilepticus. The company is targeting the global acute repetitive seizures market, valued at $3.15 billion in 2024 with projected CAGR of 12.7% from 2025-2030.
The studies will be conducted in collaboration with Professor Fabio Sonvico from the University of Parma, focusing on developing a rapid, targeted, and patient-friendly seizure rescue therapy. The intranasal delivery system aims to provide advantages over traditional administration methods, enabling emergency responders, caregivers, and patients to administer treatment quickly in out-of-hospital settings.
Polyrizon Ltd. (NASDAQ: PLRZ) ha avviato studi preclinici su Benzodiazepine (BZDs) per somministrazione intranasale utilizzando la sua piattaforma proprietaria Trap and Target™ (T&T) per il trattamento delle crisi epilettiche ripetitive acute (ARS) e dello stato di male epilettico. L'azienda si rivolge al mercato globale delle crisi epilettiche ripetitive acute, stimato a 3,15 miliardi di dollari nel 2024 con un tasso di crescita annuale composto (CAGR) previsto del 12,7% dal 2025 al 2030.
Gli studi saranno condotti in collaborazione con il Professore Fabio Sonvico dell'Università di Parma, focalizzandosi sullo sviluppo di una terapia di emergenza per le crisi rapida, mirata e di facile utilizzo per il paziente. Il sistema di somministrazione intranasale punta a offrire vantaggi rispetto ai metodi tradizionali, permettendo a soccorritori, caregiver e pazienti di somministrare rapidamente il trattamento in contesti extraospedalieri.
Polyrizon Ltd. (NASDAQ: PLRZ) ha iniciado estudios preclínicos para Benzodiazepinas (BZDs) intranasales utilizando su plataforma patentada Trap and Target™ (T&T) para tratar crisis epilépticas repetitivas agudas (ARS) y estado epiléptico. La compañía apunta al mercado global de crisis epilépticas repetitivas agudas, valorado en 3.15 mil millones de dólares en 2024 con una tasa de crecimiento anual compuesta (CAGR) proyectada del 12.7% entre 2025 y 2030.
Los estudios se realizarán en colaboración con el Profesor Fabio Sonvico de la Universidad de Parma, enfocándose en desarrollar una terapia de rescate para convulsiones rápida, dirigida y fácil de usar para el paciente. El sistema de administración intranasal busca ofrecer ventajas sobre los métodos tradicionales, permitiendo que los socorristas, cuidadores y pacientes administren el tratamiento rápidamente en entornos fuera del hospital.
Polyrizon Ltd. (NASDAQ: PLRZ)는 급성 반복 발작(ARS) 및 지속발작 치료를 위해 독자적인 Trap and Target™ (T&T) 플랫폼을 활용한 비강 투여 벤조디아제핀(BZDs) 전임상 연구를 시작했습니다. 회사는 2024년 31억 5천만 달러 규모의 글로벌 급성 반복 발작 시장을 목표로 하며, 2025년부터 2030년까지 연평균 성장률(CAGR) 12.7%가 예상됩니다.
이 연구는 파르마 대학교의 파비오 손비코 교수와 협력하여 빠르고 표적화된 환자 친화적 발작 구제 치료법 개발에 중점을 둡니다. 비강 투여 시스템은 기존 투여 방법 대비 장점을 제공하여 응급 구조자, 간병인 및 환자가 병원 외 환경에서 신속하게 치료를 시행할 수 있도록 합니다.
Polyrizon Ltd. (NASDAQ : PLRZ) a lancé des études précliniques sur les benzodiazépines (BZDs) par voie intranasale en utilisant sa plateforme propriétaire Trap and Target™ (T&T) pour traiter les crises épileptiques répétitives aiguës (ARS) et le status epilepticus. L'entreprise cible le marché mondial des crises épileptiques répétitives aiguës, estimé à 3,15 milliards de dollars en 2024 avec un taux de croissance annuel composé (CAGR) prévu de 12,7 % entre 2025 et 2030.
Les études seront menées en collaboration avec le Professeur Fabio Sonvico de l'Université de Parme, avec un focus sur le développement d'un traitement de secours rapide, ciblé et facile à utiliser pour les patients. Le système d'administration intranasale vise à offrir des avantages par rapport aux méthodes traditionnelles, permettant aux intervenants d'urgence, aux aidants et aux patients d'administrer rapidement le traitement en dehors des établissements hospitaliers.
Polyrizon Ltd. (NASDAQ: PLRZ) hat präklinische Studien zu intranasalen Benzodiazepinen (BZDs) unter Verwendung ihrer proprietären Trap and Target™ (T&T) Plattform zur Behandlung von akuten wiederkehrenden Anfällen (ARS) und Status epilepticus eingeleitet. Das Unternehmen zielt auf den globalen Markt für akute wiederkehrende Anfälle ab, der im Jahr 2024 auf 3,15 Milliarden US-Dollar geschätzt wird und von 2025 bis 2030 eine prognostizierte jährliche Wachstumsrate (CAGR) von 12,7 % aufweist.
Die Studien werden in Zusammenarbeit mit Professor Fabio Sonvico von der Universität Parma durchgeführt und konzentrieren sich auf die Entwicklung einer schnellen, gezielten und patientenfreundlichen Notfalltherapie bei Anfällen. Das intranasale Verabreichungssystem soll Vorteile gegenüber herkömmlichen Methoden bieten und es Ersthelfern, Betreuern und Patienten ermöglichen, die Behandlung schnell außerhalb des Krankenhauses anzuwenden.
- Targeting large market opportunity of $3.15B with strong growth potential (12.7% CAGR)
- Collaboration with leading expert Professor Fabio Sonvico enhances development credibility
- Platform potentially offers advantages over traditional treatment methods for emergency situations
- Company still in early development stage with preclinical studies just beginning
- No guarantee of successful trial outcomes or regulatory approval
- Faces competition in established BZD market
Insights
Polyrizon's new preclinical program for intranasal Benzodiazepines targets a growing $3.15B epilepsy market with potential delivery advantages.
Polyrizon's announcement represents an early-stage development in their pipeline, specifically targeting the acute repetitive seizures (ARS) market valued at
The scientific rationale is sound. BZDs are well-established as first-line treatments for acute seizures due to their enhancement of GABA inhibitory effects in the central nervous system. The current challenge in epilepsy management isn't finding effective compounds but rather optimizing their delivery for emergency situations.
What makes this development potentially valuable is the route of administration. Intranasal delivery offers distinct advantages over traditional methods: it bypasses first-pass metabolism, can provide rapid onset of action through direct nose-to-brain pathways, and enables administration by non-medical personnel in emergency settings. For seizure rescue therapy, these minutes saved can be critical.
However, this program is still in preclinical stages - the earliest phase of drug development. Many promising preclinical candidates fail to advance to clinical trials due to efficacy, safety, or formulation challenges. The collaboration with Professor Fabio Sonvico provides scientific credibility, but investors should recognize that commercialization, if successful, would be years away.
The company is targeting a growing market with projected
Raanana, Israel, May 13, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development stage biotech company specializing in the development of innovative intranasal hydrogels, recently announced the initiation of preclinical studies for intranasal Benzodiazepines (BZDs), a first-line treatment for acute repetitive seizures (ARS) and status epilepticus, using its proprietary drug delivery platform.
According to the World Health Organization (WHO), epilepsy is a neurological condition affecting about 50 million people worldwide. Many existing therapies fail to provide adequate control of acute repetitive seizures and may come with undesirable adverse effects. The global acute repetitive seizures market size was estimated at USD 3.15 billion in 2024 and is projected to grow at a CAGR of
The study will be conducted in collaboration with Professor Fabio Sonvico, Associate Professor at the Department of Food and Drug of the University of Parma (Italy) a leading expert in the development of intranasal and pulmonary drug delivery solutions and a member of the Company’s Scientific Advisory Board.
These preclinical studies mark a step forward in evaluating Polyrizon’s Trap and Target™ (T&T) platform for the intranasal administration of Benzodiazepine, designed to enable rapid, targeted, and patient-friendly seizure rescue therapy.
BZDs are well-established, first-line drugs for the acute treatment of seizures. They act by enhancing the inhibitory effects of gamma-aminobutyric acid (GABA) at the GABA-A receptor in the central nervous system, helping to quickly suppress seizure activity.
Intranasal delivery of BZDs offers multiple advantages over traditional routes of administration, including ease of use and increased accessibility. This approach allows emergency responders, caregivers and at-risk individuals to administer life-saving medication rapidly and independently in out-of-hospital settings.
“Launching this preclinical program marks an important milestone in our initiative to improve emergency treatment options for epilepsy patients,” said Tomer Izraeli, CEO of Polyrizon. “We believe our intranasal delivery platform has the potential to offer a faster, safer and more accessible solution for managing acute seizures outside of clinical settings.”
About Polyrizon
Polyrizon is a development stage biotech company specializing in the development of innovative medical device hydrogels delivered in the form of nasal sprays, which form a thin hydrogel-based shield containment barrier in the nasal cavity that can provide a barrier against viruses and allergens from contacting the nasal epithelial tissue. Polyrizon’s proprietary Capture and Contain TM, or C&C, hydrogel technology, comprised of a mixture of naturally occurring building blocks, is delivered in the form of nasal sprays, and potentially functions as a “biological mask” with a thin shield containment barrier in the nasal cavity. Polyrizon are further developing certain aspects of our C&C hydrogel technology such as the bioadhesion and prolonged retention at the nasal deposition site for intranasal delivery of drugs. Polyrizon refers to its additional technology, which is in an earlier stage of pre-clinical development, that is focused on nasal delivery of active pharmaceutical ingredients, or APIs, as Trap and Target ™, or T&T. For more information, please visit https://polyrizon-biotech.com.
Forward Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses its initiative to improve emergency treatment options for epilepsy patients, its belief that its intranasal delivery platform has the potential to offer a faster, safer and more accessible solution for managing acute seizures outside of clinical settings and the expected growth of the global acute repetitive seizures market. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report filed with the SEC on March 11, 2025 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Polyrizon is not responsible for the contents of third-party websites.
Contacts:
Michal Efraty
Investor Relations
FAQ
What is the market size for Polyrizon's (PLRZ) epilepsy treatment target market?
What is Polyrizon's (PLRZ) approach to treating epilepsy?
Who is collaborating with Polyrizon (PLRZ) on their epilepsy treatment studies?
What stage of development is Polyrizon's (PLRZ) epilepsy treatment in?
What advantages does Polyrizon's (PLRZ) intranasal delivery system offer?
